These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 28043863)
1. Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers. England RM; Hare JI; Barnes J; Wilson J; Smith A; Strittmatter N; Kemmitt PD; Waring MJ; Barry ST; Alexander C; Ashford MB J Control Release; 2017 Feb; 247():73-85. PubMed ID: 28043863 [TBL] [Abstract][Full Text] [Related]
2. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. Fujita K; Kubota Y; Ishida H; Sasaki Y World J Gastroenterol; 2015 Nov; 21(43):12234-48. PubMed ID: 26604633 [TBL] [Abstract][Full Text] [Related]
3. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416 [TBL] [Abstract][Full Text] [Related]
4. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150 [TBL] [Abstract][Full Text] [Related]
6. Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38. Mathijssen RH; Verweij J; Loos WJ; de Bruijn P; Nooter K; Sparreboom A Br J Cancer; 2002 Jul; 87(2):144-50. PubMed ID: 12107833 [TBL] [Abstract][Full Text] [Related]
7. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544 [TBL] [Abstract][Full Text] [Related]
8. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350 [TBL] [Abstract][Full Text] [Related]
9. Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics. Tamura T; Yasutake K; Nishisaki H; Nakashima T; Horita K; Hirohata S; Ishii A; Hamano K; Aoyama N; Shirasaka D; Kamigaki T; Kasuga M Oncology; 2004; 67(5-6):327-37. PubMed ID: 15713987 [TBL] [Abstract][Full Text] [Related]
10. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy. Lee SY; Yang CY; Peng CL; Wei MF; Chen KC; Yao CJ; Shieh MJ Biomaterials; 2016 Apr; 86():92-105. PubMed ID: 26896610 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats. Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577 [TBL] [Abstract][Full Text] [Related]
12. Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. Paulík A; Grim J; Filip S Acta Medica (Hradec Kralove); 2012; 55(4):153-9. PubMed ID: 23631285 [TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479 [TBL] [Abstract][Full Text] [Related]
14. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle. Burris HA; Infante JR; Anthony Greco F; Thompson DS; Barton JH; Bendell JC; Nambu Y; Watanabe N; Jones SF Cancer Chemother Pharmacol; 2016 May; 77(5):1079-86. PubMed ID: 27061418 [TBL] [Abstract][Full Text] [Related]
15. Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered. Vénat-Bouvet L; Saint-Marcoux F; Lagarde C; Peyronnet P; Lebrun-Ly V; Tubiana-Mathieu N Anticancer Drugs; 2007 Sep; 18(8):977-80. PubMed ID: 17667606 [TBL] [Abstract][Full Text] [Related]
16. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Stewart CF; Zamboni WC; Crom WR; Houghton PJ Cancer Chemother Pharmacol; 1997; 40(3):259-65. PubMed ID: 9219511 [TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940 [TBL] [Abstract][Full Text] [Related]
18. Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice. Huisman SA; de Bruijn P; Ghobadi Moghaddam-Helmantel IM; IJzermans JN; Wiemer EA; Mathijssen RH; de Bruin RW Br J Pharmacol; 2016 Mar; 173(5):804-14. PubMed ID: 26332723 [TBL] [Abstract][Full Text] [Related]
19. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice. Chu C; Abbara C; Tandia M; Polrot M; Gonin P; Farinotti R; Bonhomme-Faivre L Fundam Clin Pharmacol; 2014 Dec; 28(6):652-60. PubMed ID: 24588516 [TBL] [Abstract][Full Text] [Related]
20. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. Kim KP; Kim HS; Sym SJ; Bae KS; Hong YS; Chang HM; Lee JL; Kang YK; Lee JS; Shin JG; Kim TW Cancer Chemother Pharmacol; 2013 Jun; 71(6):1609-17. PubMed ID: 23595344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]